Prospects for Bayer's oral Factor XIa inhibitor asundexian were looking speculative when it failed a phase 3 trial in atrial fibrillation (AF), but new data in secondary stroke prevention could get ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback